ALDEYRA THERAPEUTICS INC

Company Overview

Aldeyra Therapeutics (ALDX) is a clinical‑stage biotechnology company developing RASP (reactive aldehyde species) modulators across ophthalmic, retinal and systemic inflammatory/metabolic indications. Its lead asset reproxalap is a topically administered candidate in late‑stage development for dry eye disease and allergic conjunctivitis (NDA accepted with a prior PDUFA date referenced), and other programs include intravitreal ADX‑12191 (FDA orphan designation for retinitis pigmentosa) and multiple preclinical oral RASP candidates. The company outsources manufacturing and trials, operates with a very small internal headcount (9 FTEs at year‑end 2024), is R&D‑intensive (2024 R&D expense $48.2M; net loss $55.9M), and depends materially on regulatory outcomes, potential partnership/exercise of the AbbVie option, and periodic financing.

Executive Compensation Practices

Given Aldeyra’s lack of marketed products, heavy R&D spend and limited cash runway, executive pay is likely skewed toward equity‑linked compensation (stock options/RSUs and milestone‑based awards) to conserve cash and align management with long‑dated clinical and regulatory outcomes. Short‑term cash incentives, if used, are typically tied to near‑term program milestones (e.g., NDA filings/acceptance, PDUFA decisions, pivotal trial enrollments) and operational metrics such as budget/cash‑burn management; long‑term incentives focus on successful partnering or commercialization events (e.g., potential AbbVie option exercise and milestone receipts). Retention awards, change‑in‑control protections, and performance vesting are common in small biotech to prevent turnover during critical development windows, and benchmarking is usually against small/mid‑cap biotech peers rather than large pharma given differing risk profiles and liquidity constraints.

Insider Trading Considerations

Insider trading activity at Aldeyra will likely cluster around a handful of material events — NDA submissions/acceptance, PDUFA actions, pivotal trial readouts, and partnership/option decisions with AbbVie — and such transactions can be highly informative given the company’s concentrated insider ownership and small float. Expect routine use of trading restrictions: blackout periods around clinical/regulatory milestones, pre‑arranged Rule 10b5‑1 plans for scheduled diversification, and caution around confidential trial information; breaches or atypical timing may attract regulatory scrutiny. Financial pressures (increased cash burn, outstanding Hercules term loan and the availability of an ATM program) can also influence the pace and necessity of equity grants and insider sales, so watch for clustered insider selling tied to financing cycles or immediately after positive partnership/approval news that reduces informational asymmetry.